6-isobutyl-pyridin-2-ol | 856965-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-isobutyl-pyridin-2-ol
• 英文别名: 6-Isobutylpyridin-2-ol；6-(2-methylpropyl)-1H-pyridin-2-one
• CAS: 856965-60-1
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: YNEYWBNBTJFALT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-isobutyl-pyridin-2-ol 在 盐酸 、 五氯化磷 、 钯 、 三氯氧磷 作用下， 生成 2-异丁基吡啶
  参考文献：
  名称：

  Condensations of Unsymmetrical Ketones. I. Condensations with Ethyl Formate

  摘要：

  DOI：

  10.1021/ja01203a032
• 作为产物：
  描述：

  6-异丙基-2-氧代-1,2-二氢-吡啶-3-羧酸 生成 6-isobutyl-pyridin-2-ol
  参考文献：
  名称：

  Condensations of Unsymmetrical Ketones. I. Condensations with Ethyl Formate

  摘要：

  DOI：

  10.1021/ja01203a032

文献信息

• TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20160137639A1

  公开（公告）日：2016-05-19

  A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.

  由式[I]表示的化合物： 或其药学上可接受的盐，其中每个符号如描述中所定义。
• Indoleamine 2,3-dioxygenase inhibitor and application
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US11046679B2

  公开（公告）日：2021-06-29

  The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R1, R2, R3, R1a, R2a, m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO).

  本发明属于医疗技术领域。特别是，本发明涉及一种式（I）所示的化合物、其药学上可接受的盐及其立体异构体。X、Y、Z、R1、R2、R3、R1a、R2a、m 和 n 如说明书中所定义。本发明还涉及这些化合物的药物制剂和药物组合物及其在制备治疗由异常吲哚胺 2，3-二氧 化酶（IDO）介导的相关疾病的药物中的用途。
• PYRUVATE KINASE MODULATORS AND USE THEREOF
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US20200206225A1

  公开（公告）日：2020-07-02

  Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.
• INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US20200181131A1

  公开（公告）日：2020-06-11

  The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R 1 , R 2 , R 3 , R 1a , R 2a , m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO).
• PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US20220395503A1

  公开（公告）日：2022-12-15

  Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R 1 , R 2 , L 1 , and L 2 are as defined herein.